Fig. 6From: Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapyDistribution of anti-Spike IgG medians by months in CoronaVac and BNT162b2 groups (*median anti-Spike IgG levels were shown) (IS: Immunosuppressive group, HC: Healthy controls)Back to article page